These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26707267)

  • 1. Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Vokó Z; Akhras KS; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):15-6. PubMed ID: 26707267
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
    Carapinha JL
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):11-4. PubMed ID: 26707161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
    Danzon PM
    Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the impact of global price interdependencies.
    Richter A
    Pharmacoeconomics; 2008; 26(8):649-59. PubMed ID: 18620459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of studies reporting actual prices for medicines.
    Mardetko N; Kos M; Vogler S
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.
    Elek P; Takács E; Merész G; Kaló Z
    Health Policy Plan; 2017 Apr; 32(3):349-358. PubMed ID: 27697777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
    Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
    Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of regulation on drug launch and pricing in interdependent markets.
    Danzon PM; Epstein AJ
    Adv Health Econ Health Serv Res; 2012; 23():35-71. PubMed ID: 23156660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?
    Kanavos P; Kamphuis BW; Fontrier AM; Colville Parkin G; Saleh S; Akhras KS
    Health Policy; 2020 Dec; 124(12):1297-1309. PubMed ID: 32962876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of parallel trade on pharmaceutical firm's profits: rise or fall?
    Guo S; Hu B; Zhong H
    Eur J Health Econ; 2013 Apr; 14(2):345-55. PubMed ID: 22286662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the Value of Pharmaceuticals in the US Health System.
    Walton SM; Basu A; Mullahy J; Hong S; Schumock GT
    Pharmacoeconomics; 2017 Jan; 35(1):1-4. PubMed ID: 27785770
    [No Abstract]   [Full Text] [Related]  

  • 20. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.